Research Beam added a report on “Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 ” Enquiry about report: http://www.researchbeam.com/type-2-diabetes-mellitus-therapeutics-in-asia-pacific-to-2021-increasing-usage-of-newer-therapies-and-expanding-treatment-population-to-encourage-robust-growth-market/enquire-about-report

1. Type 2 Diabetes Mellitus Therapeutics in
Asia-Pacific Markets to 2021 - Increasing
Usage of Newer Therapies and Expanding
Treatment Population to Encourage Robust
Growth
TELEPHONE: +1 (503) 894-6022
E-MAIL: sales@researchbeam.com

2. Report Overview
Scope
The current T2DM in the Asia-Pacific (APAC) market contains novel products, including Jardiance - a SGLT-
2 inhibitor; Victoza - a GLP-1 receptor agonist; and Galvus - a DPP-4 inhibitor.
- What are the competitive advantages of the existing novel drugs?
With over 500 active pipeline molecules, most of the late-stage investigational drug candidates are being
evaluated, featuring improved dosing regimens and administration routes, in comparison to currently
marketed products and combination therapies.
- Which classes of novel drugs are most prominent within the pipeline?
- Is there strong potential for the pipeline to address unmet needs within the T2DM market?
Analysis of clinical trials, since 2006, identified that the failure rates of T2DM molecules were highest in
Phase II, at 54%, with the overall attrition rate for T2DM at 82.6%.
- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors, such as average trial duration and trial size influence the costs and risks
associated with product development?
Read More At: http://www.researchbeam.com/type-2-diabetes-mellitus-therapeutics-in-asia-pacific-
to-2021-increasing-usage-of-newer-therapies-and-expanding-treatment-population-to-encourage-
robust-growth-market

3. Table of Content
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 9
2.1 Disease Overview 9
2.2 Classification 9
3 Marketed Products 43
3.1 Overview 43
3.2 Biguanides 44
4 Pipeline 70
4.1 Overview 70
4.2 Pipeline Distribution by Stage of Development, Molecule Type and Program Type 71
5 Market Forecast to 2021 99
5.1 Geographical Markets 99
5.2 Asia-Pacific Markets 99
6 Strategic Consolidations 113
6.1 Licensing Deals 113
6.2 Co-development Deals 120
7 Appendix 129
7.1 All Pipeline Drugs by Phase of Development 129
7.2 Market Forecasts to 2021 146

4. Report Overview
Reasons to buy
This report will enable you to -
- Understand the clinical context of T2DM by considering symptoms, etiology, pathophysiology,
epidemiology, diagnosis, and treatment options.
- Identify the therapeutic strategies, products, and companies that dominate the current marketed
products landscape and recognize gaps and areas of unmet need.
- Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
- Consider market opportunities and potential risks by examining trends in T2DM clinical trial size,
duration, and failure rate by stage of development, molecule type, and mechanism of action.
- Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in
T2DM by examining clinical trial data and multi-scenario product forecast projections.
- Compare treatment usage patterns, annual therapy costs, and market growth projections for China,
India, Australia, and Japan.
- Discover trends in licensing and co-development deals concerning T2DM products and identify the major
strategic consolidations that have shaped the commercial landscape.
Enquire At : http://www.researchbeam.com/type-2-diabetes-mellitus-therapeutics-in-asia-pacific-to-
2021-increasing-usage-of-newer-therapies-and-expanding-treatment-population-to-encourage-robust-
growth-market/enquire-about-report

5. FOR MORE DETAILS
Visit us at :
Stay With Us:
http://www.researchbeam.com/type-2-diabetes-mellitus-therapeutics-in-asia-pacific-to-2021-
increasing-usage-of-newer-therapies-and-expanding-treatment-population-to-encourage-robust-
growth-market
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States
TELEPHONE: +1 (800) 910-6452
DIRECT: +1 (503) 894-6022
E-MAIL: sales@researchbeam.com